CyDex Pharmaceuticals, Inc. (CyDex) is a privately held specialty pharmaceutical company, engaged in the commercialization, research and development of drugs designed to meet the limitations of existing therapies. The company offers its products for the treatment of bipolar disorder, schizophrenia, fungal infections and canine motion sickness. It also develops treatments for status epilepticus, multiple myeloma, epilepsy, arrhythmia, asthma, atherothrombosis and allergic rhinitis. The company develops its portfolio of product candidates utilizing its drug formulation technology using Captisol, a group of cyclodextrins. CyDex partnered with some of the industry majors for development and commercialization of its products. The company also out licenses its technology to third parties for use in the development of therapeutics. CyDex Pharmaceuticals, Inc. was previously known as CyDex, Inc. The company is headquartered in Lenexa, Kansas, the US. Recently, the company announced the initiation of patient dosing for Phase 2A clinical trial of its Captisol-Enabled Melphalan HCL (CDX-353) with Alkeran.